Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Research & Development (2022 - 2025)

Historic Research & Development for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to $2.9 million.

  • Atara Biotherapeutics' Research & Development fell 9334.08% to $2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.4 million, marking a year-over-year decrease of 6148.28%. This contributed to the annual value of $151.5 million for FY2024, which is 3260.98% down from last year.
  • As of Q3 2025, Atara Biotherapeutics' Research & Development stood at $2.9 million, which was down 9334.08% from $7.3 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Research & Development registered a high of $75.0 million during Q1 2022, and its lowest value of $2.9 million during Q3 2025.
  • In the last 4 years, Atara Biotherapeutics' Research & Development had a median value of $49.6 million in 2023 and averaged $45.8 million.
  • As far as peak fluctuations go, Atara Biotherapeutics' Research & Development tumbled by 1349.35% in 2023, and later plummeted by 9334.08% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Research & Development stood at $62.5 million in 2022, then decreased by 20.66% to $49.6 million in 2023, then crashed by 42.09% to $28.7 million in 2024, then tumbled by 89.82% to $2.9 million in 2025.
  • Its Research & Development stands at $2.9 million for Q3 2025, versus $7.3 million for Q2 2025 and $27.4 million for Q1 2025.